Highlights from the report produced by the third Lancet Commission on Dementia Prevention, Intervention, and Care were presented on 31 July at the 2024 Alzheimer’s Association International Conference (AAIC). Previous commission reports in 2017 and 2020 also argued for preventive strategies that target modifiable risk factors associated with cognitive impairment. The 2024 report expands the list to 14 health factors that are potential targets for preventive measures: cardiovascular disease, especially…READ MORE

At the 2019 Alzheimer’s Association International Conference, July 14-18, in Los Angeles, California, uMETHOD Health shared results from an analysis that evaluated the implementation of a precision-medicine platform to create personalized, multidomain care plans for the treatment of dementia and mild Alzheimer disease. The algorithms analyze medication interactions and adverse drug reactions, such as drug-drug interactions, opioid usage, anticholinergic cognitive burden, and depression-inducing drugs, rate them using input from an open-source…READ MORE

Polypharmacy is a growing problem in the United States. The use of multiple medications increases the likelihood that a patient will experience potential drug interactions and adverse drug reactions (ADRs). Those individuals with dementia or Alzheimer’s disease (AD) are at greater risk, due to age, comorbidities, and an increased likelihood of being on a greater number of neuroactive medications. ... The results of this work show that older populations have…READ MORE